AI Consensus Investment Thesis
AstraZeneca (AZN) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Strong Buy & Hold
High conviction across horizons supports patient long-term ownership.
1-Year
STRONG BUY15,311 GBX
+30.8%+33.6% incl. dividends5-Year
BUY21,308 GBX
+82.1%+102.0% incl. dividendsLatest flagship insight
Why the Market Misprices This Biopharma Giant's Hidden Supply Chain Arbitrage
Input reports show a sharp divergence regarding this biopharma asset. While high consensus exists on its core oncology dominance, opinions clash over massive domestic manufacturing capital expenditures and regulatory pricing pressures. The primary driver remains pipeline execution, while geopolitical supply chain decoupling represents the ultimate downside risk.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
This biopharma asset represents a highly resilient, cash-generative compoundercompounderA business or asset that can reinvest earnings or cash flows at attractive returns over an extended period.View full glossary entry navigating a challenging stagflationary macro regimestagflationary macro regimeA persistent macroeconomic environment combining weak growth with persistent inflation.View full glossary entry. The core investment thesis centers on its structural oncology dominance and rare disease pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, which effectively insulate operating cash flows from inflationary pressures and economic downturns. However, a sharp analytical divergence exists regarding the capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry of its massive domestic manufacturing reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry and its geopolitical exposure. While some perspectives view these heavy capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry as a defensive tax that compresses near-term free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, others identify them as a critical sovereign moat that secures long-term supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry integrity in a fragmenting global landscape.
Key insights
- Core oncology and rare disease portfolios provide highly inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry and robust pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, shielding margins from inflationary shocks.
- Massive capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry for domestic manufacturing reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry temporarily depress free cash flow marginsfree cash flow marginsThe percentage of revenue converted into cash after accounting for capital expenditures and operating costs.View full glossary entry but secure long-term sovereign alignment.
- Geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry mandates introduce supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry transition risks and R&D cost inflation, particularly regarding Asian partnerships.
- Advanced computational biology and machine learning integration structurally accelerate pipeline development timelines and improve clinical success probabilities.
- Regulatory pricing frameworks in key Western markets impose a persistent ceiling on terminal margins, limiting multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry.
- Pristine balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry leverage provides substantial downside protection and counter-cyclical acquisition optionality in a tight liquidity environment.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative views the asset as a high-quality, defensive pharmaceutical giant with a highly predictable oncology franchise. The crowd is heavily focused on near-term clinical trial readouts and the company's ambitious long-term revenue targets. However, there is widespread anxiety regarding impending patent cliffs for legacy blockbuster drugs and the threat of government-mandated drug pricing reforms in the United States. Most analysts treat the company's premium valuation as a justified quality tax for its defensive profile, while largely overlooking the capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry of its supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry restructuring and treating its geopolitical exposure as a manageable footnote.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's mispricing of the company's geopolitical supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry strategy and its technological transition. While the crowd views massive capital commitments to domestic manufacturing reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry as a near-term drag on margins, this proactive spending actually converts geopolitical riskgeopolitical riskThe potential for political instability or international tensions to negatively impact business operations and valuation.View full glossary entry into a proprietary competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry. Less capitalized peers will suffer severe disruptions, while this company secures sovereign-compliant capacity. Furthermore, the market systematically underestimates the non-linear efficiency gains from the early integration of artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry and computational biology into the research and development pipeline. Rather than a legacy pharmaceutical manufacturer, the company is transitioning into a highly efficient biological platform, a structural shift that traditional valuation models fail to capture.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence catalyst that will force the market to align with this consensus is a combination of upcoming Phase III clinical trial readouts for key pipeline assets and the operational launch of new domestic manufacturing hubs. When the company demonstrates a structural reduction in drug development timelines driven by computational biology, alongside margin resilience despite geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry, the market will be forced to revalue the asset. This empirical proof of accelerated research productivity and supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry security will trigger a significant upward revision of the company's long-term valuation.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Moderate
- Cycle position
- Growing Awareness
While there is broad agreement that the asset is in a phase of growing awareness, a sharp divergence exists regarding volatility and sentiment. Some perspectives view the stock as a low-volatility safe haven, while others warn of high, erratic volatility driven by impending regulatory pricing shocks and geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry risks.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, elevated interest rates, and geopolitical fragmentationgeopolitical fragmentationStructural shifts in global trade and policy impacting international business operations and market access.View full glossary entry presents a highly favorable tailwind for the company's defensive cash flows, but a headwind for its premium valuation multiple. Inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry for life-saving oncology and rare disease treatments perfectly insulates operating revenues from inflationary pressures and economic downturns. Additionally, a high-rate environment restricts funding for smaller biotech competitors, protecting the company's market dominance. However, tighter global liquidityglobal liquidityThe availability and ease of financing across major global markets, currencies, and financial institutions.View full glossary entry and rising discount rates limit further multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry, making future equity returns highly dependent on internal earnings growth and operational execution.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the long-term impact of the company's massive capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry program. One perspective views the multi-billion-dollar domestic manufacturing reshoringreshoringMoving production or supply operations back to the domestic market from overseas locations.View full glossary entry commitment as a defensive, politically forced tax that will severely compress free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry and destroy shareholder value. Conversely, another perspective argues that this capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry is a visionary investment that secures supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry sovereignty and builds an impenetrable geopolitical moat. Additional disagreements emerge regarding the timeline and probability of success for the company's oral metabolic pipeline.
Base-Case Forces
Event Risk ScoreVery Low19/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Oncology Pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry Dominance | Competitive Positioning | +25% | +30% | The company's robust oncology portfolio, led by advanced antibody-drug conjugates and targeted therapies, forms an unassailable competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry. By establishing the standard of carestandard of careThe accepted medical practice or diagnostic protocol used by clinicians to treat specific patient conditions.View full glossary entry across multiple solid tumors, the company secures highly durable, inelastic revenue streams. Continuous label expansions into earlier lines of therapy expand the total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry, driving long-term earnings growth. |
| Rare Disease Pricing Powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry | Capital Allocation | +15% | +18% | The integration of specialized rare disease franchises provides exceptional pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry. Because alternative treatments are virtually non-existent, this segment is highly insulated from macroeconomic shocks and populist political pressures. The resulting predictable cash flows fund wider research and development initiatives, compounding long-term value. |
| Computational Biology and AI Integrationai integrationIncorporating artificial intelligence into existing business processes to enhance service delivery and value.View full glossary entry | Innovation And Product | +18% | +15% | Aggressive integration of artificial intelligenceartificial intelligenceComputer systems designed to perform tasks that ordinarily require human perception, reasoning, learning, language, or decision-making.View full glossary entry and machine learning into drug discovery and clinical trial design structurally reduces development timelines and trial attrition rates. By transforming drug development into a predictive science, the company improves research and development efficiency, driving structurally higher returns on invested capitalreturns on invested capitalAfter-tax operating profit generated relative to the capital invested in operations.View full glossary entry. |
| Defensive StagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry Resilience | Macroeconomic And Macrofinancial | +10% | +5.0% | In a stagflationary macro environmentstagflationary macro environmentA broad economic environment combining weak growth with persistent inflation.View full glossary entry characterized by sticky inflation and high interest rates, defensive capital rotates into high-margin, cash-generative assets. The company's inelastic demandinelastic demandDemand that changes proportionally less than price over a defined range and period.View full glossary entry and robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry provide a safe harbor, insulating the stock from broader equity multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry and ensuring steady capital inflows. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Regulatory Pricing Compression | Regulatory | -15% | -12% | Populist drug pricing initiatives and government-mandated price negotiations in key Western markets, particularly the United States, impose a structural ceiling on profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry. These regulatory interventions directly threaten the terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry of blockbuster assets, forcing the company to rely on volume expansion rather than price hikes. |
| Geopolitical Decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry and Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry Realignment | Political And Geopolitical | -12% | -8.0% | Deep operational exposure to international markets and reliance on global clinical trial networks create severe vulnerabilities amid accelerating geopolitical decouplinggeopolitical decouplingA reduction in trade, investment, technology exchange, or supply-chain integration between countries or geopolitical blocs.View full glossary entry. Compliance with restrictive trade acts forces a costly, multi-year supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry realignment, introducing transition risks and inflating research and development costs. |
| Patent Cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry Erosion | Competitive Positioning | -10% | -12% | The loss of exclusivityloss of exclusivityRefers to the expiration of patent protection leading to generic or biosimilar competition for key drugs.View full glossary entry on legacy blockbuster cardiovascular and metabolic therapies creates a persistent revenue drag. As generic and biosimilar competitionbiosimilar competitionCompetition from highly similar versions of an approved biologic medicine after exclusivity or market protections weaken.View full glossary entry erodes mature asset revenues, the company's pipeline must execute flawlessly to replace lost high-margin sales and maintain top-line growth momentum. |
| Elevated Capital Expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry Burden | Capital Allocation | -8.0% | -5.0% | The massive capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry required to re-shore biomanufacturing and support dozens of concurrent Phase III clinical trials acts as a near-term drag on free cash flow conversionfree cash flow conversionThe proportion of earnings, EBITDA, or another operating measure converted into free cash flow over a specified period.View full glossary entry. This capital-heavy posture limits the capacity for aggressive share repurchases, tethering near-term shareholder returns strictly to clinical outcomes. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Draconian Price Controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry | 20% | -25% | Regulatory | Coordinated Western legislation implementing non-negotiable price caps on specialized oncology and rare disease therapies in response to sovereign debtsovereign debtDebt issued or guaranteed by a national government.View full glossary entry crises. This extreme regulatory intervention would destroy the company's absolute pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry, collapsing terminal valuationsterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry and permanently impairing long-term capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry models. |
| High-Profile Pipeline Failure | 15% | -20% | Innovation And Product | A catastrophic clinical trial failure or unexpected safety signal for a key late-stage oncology asset. Such an event would instantly evaporate billions in projected future cash flows and shatter market confidence in the reliability of the company's research and development engine, triggering severe multiple contraction. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Obesity Market Disruption | 35% | +20% | Competitive Positioning | If the company's oral metabolic pipeline asset demonstrates superior weight-loss efficacy and tolerability in Phase III trials, it will forcefully disrupt the existing injectable obesity duopoly. Capturing a meaningful share of this massive global market would inject highly profitable, unforecasted revenue streams, triggering rapid multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. |
| AI-Driven Pipeline Breakthrough | 25% | +25% | Innovation And Product | A systemic breakthrough where the company's deep investments in computational biology yield a verifiable collapse in clinical trial failure rates. Transitioning drug development into a highly predictive science would allow the rapid generation of first-in-class blockbusters, structurally elevating the company's long-term return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. |
Company Financial Analysis
AstraZeneca Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company is currently showing exceptional financial strength, with revenues growing steadily and net income surging significantly. This strong performance is driven by the massive success of its cancer and rare disease treatments, which remain in high demand regardless of economic conditions. The reports generally agree that the company's ability to generate cash is highly reliable, making it a safe haven during periods of high inflation. However, there is a clear disagreement regarding the future outlook. Some analysts believe this cash-printing machine will continue to accelerate as new drugs are launched. In contrast, others warn that upcoming price cuts mandated by governments and the loss of patents on older drugs will soon eat into profits, potentially leading to a sharp slowdown in earnings growth over the next few years.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 58.7B | USD 10.2B | USD 8.7B |
| 2024 | USD 52.9B | USD 6.9B | USD 7.3B |
| 2023 | USD 46.6B | USD 6.1B | USD 6.6B |
| 2022 | USD 44.3B | USD 3.3B | USD 7.2B |
| 2021 | USD 37.1B | USD 109.9M | USD 3.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 28.3x | TTM | USD-normalized | GBX / USD |
| 2024 | 29.1x | TTM | USD-normalized | GBX / USD |
| 2023 | 35.2x | TTM | USD-normalized | GBX / USD |
| 2022 | 64.5x | Annual | USD-normalized | GBX / USD |
| 2021 | >100x | Annual | USD-normalized | GBX / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company boasts exceptionally high profit margins, driven by its ability to set premium prices for life-saving cancer and rare disease treatments. The reports agree that these strong margins protect the company from rising costs of raw materials and energy. However, there is a major clash over where margins are headed next. Optimistic views suggest that margins will expand even further as high-value new treatments scale up and artificial intelligence makes drug discovery cheaper. Conversely, cautious perspectives warn of a looming margin squeeze. They argue that government-enforced price caps in the United States and the heavy costs of building new factories will inevitably drag profit margins down from their current peak levels, making the stock look expensive at its current valuation.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 13.7B | 23.4% | 17.4% |
| 2024 | USD 12.5B | 23.7% | 13.0% |
| 2023 | USD 9.6B | 20.5% | 13.0% |
| 2022 | USD 5B | 11.4% | 7.4% |
| 2021 | USD 2.8B | 7.6% | 0.3% |
Balance sheet and leverage
The company's balance sheet is widely considered a financial fortress, characterized by low debt levels and excellent ability to cover interest payments. The reports highly agree that this financial safety net protects the company from rising interest rates and tight credit markets. This strong position gives the company the unique ability to fund its own massive research projects without needing to borrow expensive money. Furthermore, it provides the firepower to acquire smaller, struggling biotechnology companies at bargain prices during economic downturns. While there is minor disagreement over how much new debt might be needed to fund the company's massive Western factory expansion, the overall consensus is that the balance sheet is incredibly safe and acts as a solid anchor for long-term investors.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 29.6B | USD 5.7B | USD 23.9B net debt | 0.94x |
| 2024 | USD 30.1B | USD 5.6B | USD 24.6B net debt | 0.93x |
| 2023 | USD 28.4B | USD 5.9B | USD 22.6B net debt | 0.81x |
| 2022 | USD 29.1B | USD 6.2B | USD 23B net debt | 0.86x |
| 2021 | USD 30.7B | USD 6.4B | USD 24.4B net debt | 1.16x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is spending heavily on research and development, alongside a massive multi-billion-dollar push to build new manufacturing facilities in Western countries. The reports agree that this heavy spending is necessary to move supply chains away from politically risky regions and comply with new trade regulations. However, opinions differ on what this means for investors. Some views suggest this aggressive investment is a brilliant move that secures the company's future independence and protects it from geopolitical conflicts. On the other hand, some analysts worry that this massive spending is a forced political tax that will drain the company's cash reserves, increase depreciation costs, and hurt short-term returns. Ultimately, while the spending builds a strong safety shield, it will likely limit the cash available for immediate share buybacks.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 5.9B | USD 14.2B |
| 2024 | USD 4.6B | USD 12B |
| 2023 | USD 3.8B | USD 10.5B |
| 2022 | USD 2.6B | USD 9.6B |
| 2021 | USD 2.2B | USD 8.4B |
Quarterly Forecast Scenarios
AstraZeneca Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in GBX; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (GBX) | Base Case Stock Price (GBX) | Bull Case Stock Price (GBX) | S&P 500 benchmark (USD) | Currency conversion forecast (GBP/USD) |
|---|---|---|---|---|---|
| 12,866 GBX | 14,637 GBX | 15,034 GBX | $736.09 | 1.3145 | |
| 11,837 GBX | 14,834 GBX | 15,485 GBX | $724.14 | 1.3027 | |
| 11,126 GBX | 15,125 GBX | 15,795 GBX | $713.57 | 1.3029 | |
| 10,570 GBX | 15,311 GBX | 16,427 GBX | $723.38 | 1.3004 | |
| 9,830 GBX | 15,468 GBX | 16,432 GBX | $716.61 | 1.2887 | |
| 9,437 GBX | 15,902 GBX | 17,089 GBX | $738.34 | 1.2831 | |
| 9,248 GBX | 16,209 GBX | 17,579 GBX | $746.91 | 1.2832 | |
| 9,711 GBX | 16,547 GBX | 18,634 GBX | $771.93 | 1.2856 | |
| 9,128 GBX | 16,826 GBX | 19,193 GBX | $782.73 | 1.2831 | |
| 8,672 GBX | 17,196 GBX | 19,961 GBX | $807.31 | 1.2755 | |
| 8,498 GBX | 17,649 GBX | 20,959 GBX | $822.72 | 1.2791 | |
| 8,158 GBX | 17,949 GBX | 21,588 GBX | $846.10 | 1.2810 | |
| 8,485 GBX | 18,235 GBX | 22,019 GBX | $852.53 | 1.2818 | |
| 8,230 GBX | 18,806 GBX | 23,120 GBX | $882.91 | 1.2797 | |
| 8,230 GBX | 18,946 GBX | 24,045 GBX | $900.46 | 1.2774 | |
| 8,477 GBX | 19,458 GBX | 25,488 GBX | $922.67 | 1.2737 | |
| 8,307 GBX | 19,822 GBX | 26,252 GBX | $935.91 | 1.2680 | |
| 8,474 GBX | 20,498 GBX | 27,303 GBX | $952.30 | 1.2716 | |
| 8,558 GBX | 20,736 GBX | 28,122 GBX | $976.28 | 1.2700 | |
| 8,387 GBX | 21,308 GBX | 29,246 GBX | $1,002 | 1.2674 |
Research Provenance
References & Context
This AstraZeneca consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Sources retained from AI Researcher searches
Showing the top 10 of 10 deduplicated sources retained for this batch.
Some model providers retained only the consulted domain, not an exact article URL. Those domains are shown as evidence without inventing a link.
- 01maryland.govmaryland.gov
- 02nih.govnih.gov
- 03astrazeneca-us.comastrazeneca-us.com
- 04biopharmaapac.combiopharmaapac.com
- 05clinicaloncology.comclinicaloncology.com
- 06clinicaltrialsarena.comclinicaltrialsarena.com
- 07endpoints.newsendpoints.news
- 08european-biotechnology.comeuropean-biotechnology.com
- 09fernandinaobserver.orgfernandinaobserver.org
- 10firstwordpharma.comfirstwordpharma.com
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2007-01-01–2026-01-01, 20 periods; quarterly: 2023-09-30–2026-03-31, 12 periods
Currencies cited: GBP, GBX, USD (quote GBX; primary reporting USD; converted/valuation USD; normalization GBP).